The Global Platform for Access to Childhood Cancer Medicines is a collaborative effort between the World Health Organization (WHO) and St.Jude Children’s Research Hospital. This initiative aims to expand access to essential childhood cancer medicines globally.St. Jude Children’s Research Hospital and the WHO announced a new platform that will provide children worldwide with access to cancer medicines. This initiative is part of the Six-Year St. Jude Strategic Plan. The platform offers assistance services, free of charge.
The collaboration between the WHO and St. Jude began in 2018 when St. Jude became the first WHO Collaborating center for Childhood Cancer. St. Jude committed $15 million to create the Global Initiative for Childhood Cancer, supporting over 50 governments in building and sustaining thier childhood cancer programs.
St. Jude Children’s Research Hospital was founded 63 years ago to advance cures and prevention for pediatric catastrophic diseases through research and treatment, initially focusing on childhood cancer with a survival rate of 20%.
Global Platform for Access to Childhood Cancer Medicines
Table of Contents
The Global platform for Access to Childhood Cancer Medicines is a collaborative effort between the World Health institution (WHO) and St.Jude Children’s Research Hospital. This initiative aims to expand access to essential childhood cancer medicines globally. St. Jude Children’s Research Hospital and the WHO announced a new platform that will provide children worldwide with access to cancer medicines. This initiative is part of the six-Year St. Jude Strategic Plan and offers assistance services, free of charge.
The collaboration between the WHO and St.Jude began in 2018 when St. jude became the first WHO Collaborating Center for Childhood Cancer. St. jude committed $15 million to create the Global Initiative for Childhood Cancer, supporting over 50 governments in building and sustaining their childhood cancer programs.
St. Jude Children’s research Hospital was founded 63 years ago to advance cures and prevention for pediatric catastrophic diseases through research and treatment, initially focusing on childhood cancer with a survival rate of 20%.
Q&A Session
Editor:
Can you explain the importance of the collaboration between the WHO and st.Jude Children’s Research Hospital?
Guest:
The collaboration between the WHO and St.Jude Children’s Research Hospital is a groundbreaking initiative that aims to improve access to essential childhood cancer medicines globally. By combining the expertise and resources of both organizations, this partnership seeks to address the critical need for better treatment options for children with cancer in low- and middle-income countries.
Editor:
What are the main objectives of the global Platform for Access to Childhood Cancer Medicines?
Guest:
The main objectives of the Global Platform for Access to Childhood Cancer Medicines include expanding access to essential medicines, providing technical assistance and training, and supporting governments in building sustainable childhood cancer programs. The platform offers free assistance services to ensure that more children worldwide can receive the treatment they need.
Editor:
How does this initiative fit into St. Jude’s broader strategic plan?
Guest:
This initiative is part of the Six-Year St. jude Strategic Plan, which focuses on advancing cures and prevention for pediatric catastrophic diseases. By supporting over 50 governments in building and sustaining their childhood cancer programs, St.Jude aims to make a meaningful impact on global childhood cancer treatment and survival rates.
Editor:
What are the key challenges in providing access to childhood cancer medicines globally?
Guest:
Some of the key challenges include limited resources and infrastructure, lack of trained healthcare professionals, and high costs of medicines. The Global Platform for Access to childhood Cancer Medicines addresses these challenges by providing technical assistance, training, and free access to essential medicines, thereby helping to build sustainable childhood cancer programs in low- and middle-income countries.
Editor:
What role does St. Jude Children’s Research Hospital play in this collaboration?
Guest:
St. Jude Children’s Research Hospital plays a pivotal role in this collaboration by providing expertise,resources,and financial support. Founded 63 years ago to advance cures and prevention for pediatric catastrophic diseases, St. Jude has committed $15 million to create the Global Initiative for Childhood Cancer, supporting over 50 governments in building and sustaining their childhood cancer programs.
Conclusion
The Global Platform for Access to Childhood Cancer Medicines is a significant step forward in the fight against childhood cancer. Through the collaboration between the WHO and St. Jude Children’s Research Hospital, this initiative aims to expand access to essential medicines, provide technical assistance, and support sustainable childhood cancer programs globally. By addressing key challenges and leveraging the expertise and resources of both organizations, this partnership holds the promise of improving treatment outcomes and survival rates for children with cancer worldwide.
